Peptide Dosages

Cagrilintide (10mg Vial) Dosage Protocol

Contents

Quickstart Highlights

Cagrilintide 10mg dosage protocol is designed to support weight management and metabolic control through once-weekly subcutaneous injections.
  • Slow, steady dose escalation helps minimize GI side effects
  • Once-weekly injection schedule for user convenience
  • May be reconstituted to ~3.33 mg/mL or 5 mg/mL for practical dosing
  • Store lyophilized vials in the freezer; reconstituted in the refrigerator
  • Useful for both gradual titration or higher dosing protocols
Cagrilintide (10mg Vial)
📘 Important: Before viewing any protocol, please consult our Prep & Injection Guide for essential preparation and safety instructions.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL ≈ 3.33 mg/mL)

Phase Weekly Dose (mg) Approx. Units
Weeks 1–2 0.25 mg 7.5 units
Weeks 3–4 0.5 mg 15 units
Weeks 5–8 1.0 mg 30 units
Weeks 9–12 1.7 mg 51 units
Weeks 13–16 (Optional) 2.4 mg 72 units

Ideal for moderate doses up to 2.4 mg per week. Reconstitute with 3 mL to create a ~3.33 mg/mL solution.

Reconstitution steps:

  1. Draw 3.0 mL of bacteriostatic water into a sterile syringe.
  2. Inject the water slowly along the vial wall to reduce foam.
  3. Gently swirl—avoid vigorous shaking.
  4. Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.

Advanced / Aggressive Approach (2 mL = 5 mg/mL)

If you prefer ≥10 units for the lowest dose (0.25 mg), consider using half-unit syringes or a more dilute ratio exceeding 3 mL.

Phase Weekly Dose (mg) Approx. Units
Weeks 1–2 0.25 mg 5 units
Weeks 3–4 0.5 mg 10 units
Weeks 5–8 1.0 mg 20 units
Weeks 9–12 1.7 mg 34 units
Weeks 13–16 (Optional) 2.4 mg 48 units

Recommended for higher concentration needs. Reconstitute with 2 mL to create a 5 mg/mL solution. Note that doses below 0.5 mg may be under 10 units on a standard syringe.

  1. Draw 2.0 mL of bacteriostatic water into a sterile syringe.
  2. Slowly inject the water to minimize foam.
  3. Gently roll/swirl the vial—no vigorous shaking.
  4. Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Note: This guide is for educational purposes only. Always consult with a qualified healthcare professional.

Supplies Needed

Ensure you have these on hand for an 8–16 week cycle.

  • Peptide Vials:
    • 8 wks ≈ 1 vial
    • 12 wks ≈ 2 vials
    • 16 wks ≈ 3 vials
    (Additional vials if planning higher doses)
  • Insulin Syringes:
    • 8 wks ≈ 8
    • 12 wks ≈ 12
    • 16 wks ≈ 16
  • Bacteriostatic Water: 1× 30ml
  • Alcohol Swabs: 1 box

Protocol Overview

A concise summary of this once-weekly regimen.

  • Goal: Promote weight management and metabolic control
  • Schedule: Weekly subcutaneous injections, 8–16 weeks or longer
  • Dose Range: 0.25 mg to 2.4 mg weekly via escalation
  • Reconstitution: ~3.33 mg/mL or 5 mg/mL for flexible dosing
  • Storage: Keep lyophilized vials frozen; refrigerate after reconstitution

Dosing Protocol

Suggested once-weekly injection approach for effective titration based on clinical trial data.

  • Weekly Dose: Start at 0.25 mg; gradually increase as tolerated
  • Frequency: Inject once per week subcutaneously
  • Cycle Length: 8–16 weeks (extend longer if needed for maintenance)
  • Maximum Dose (Clinical Studies): Up to 4.5 mg weekly in certain trials
  • Timing: Administer any time of day; consistency is key

Storage Instructions

Proper storage ensures peptide integrity.

  • Lyophilized: Freeze until mixing (−20°C)
  • Reconstituted: Refrigerate at 2–8°C
  • Use within 30 days of reconstitution
  • Avoid repeated freeze-thaw cycles

Important Notes

Practical tips to enhance safety and efficacy.

  • Always use new, sterile insulin syringes & rotate injection sites.
  • Maintain a consistent once-weekly schedule for optimal results.
  • Observe for gastrointestinal side effects; adjust titration if needed.
  • Monitor progress regularly, modifying dosage based on professional guidance.

How This Works

Cagrilintide is a long-acting amylin analogue investigated for its impact on appetite and metabolism.

  • Amylin Pathway: Modulates gastric emptying and enhances satiety signals
  • Metabolic Support: Aims to reduce overall caloric intake and assist weight loss
  • Complements insulin function, helping with glucose control

Potential Benefits & Side Effects

Most research participants report improved appetite regulation and moderate weight reduction.

  • May contribute to significant reductions in body weight
  • Supports improved glycemic control in some populations
  • Common side effects: nausea, GI discomfort, or mild injection site reactions
  • Serious adverse events are rare but must be monitored

Lifestyle Factors

Complementary strategies for optimal outcomes.

  • Focus on balanced, protein-rich nutrition
  • Incorporate regular physical activity and recovery practices
  • Manage stress and ensure consistent, quality sleep

Injection Technique

Simple guidelines for safe daily injections.

  • Clean vial rubber stopper & injection site with alcohol swabs
  • Insert needle at a 45–90° angle into subcutaneous tissue
  • Inject slowly & rotate sites (abdomen, thigh, etc.)

Recommended Source

We recommend Prime Lab Peptides for high-purity Cagrilintide.

Why Prime Lab Peptides?

Important Note

This guide is for educational purposes only. Always consult a qualified healthcare provider before starting or modifying any therapy.

References


PMC

– Phase 1 cagrilintide trial data


PubMed
– Clinical insights on cagrilintide

The Lancet
– Phase 3 obesity management study

UCL Discovery
– Once-weekly cagrilintide for overweight
Wiley
– Diabetes, Obesity, Metabolism journal article
The Lancet
– Full-text cagrilintide RCT findings
PubMed
– Efficacy data in obesity population
Novo Nordisk
– Official press release on cagrilintide

The Lancet
– Cagrilintide abstract in The Lancet
Pharmacy Times
– Phase 3 trials overview for cagrilintide
The Lancet
– Weight management trial abstract
Bio-Techne
– Reconstitution calculator resource
ACC.org
– CargiSema trial information